QBECP - Qu Biologics
Alternative Names: QBECP SSILatest Information Update: 20 May 2021
Price :
$50 *
At a glance
- Originator Qu Biologics
- Class Anti-inflammatories; Antineoplastics; Bacterial antigens; Cancer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bladder cancer; Prostate cancer; Renal cancer
- Research Interstitial cystitis
Most Recent Events
- 20 May 2021 Early research in Interstitial cystitis in Canada (SC) (Qu Biologics pipeline, May 2021)
- 20 May 2021 Preclinical trials in Bladder cancer in Canada (SC) (Qu Biologics pipeline, May 2021)
- 20 May 2021 Preclinical trials in Prostate cancer in Canada (SC) (Qu Biologics pipeline, May 2021)